Literature DB >> 10364306

Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4.

J A Esté1, C Cabrera, J Blanco, A Gutierrez, G Bridger, G Henson, B Clotet, D Schols, E De Clercq.   

Abstract

The emergence of X4 human immunodeficiency virus type 1 (HIV-1) strains in HIV-1-infected individuals has been associated with CD4(+) T-cell depletion, HIV-mediated CD8(+) cell apoptosis, and an impaired humoral response. The bicyclam AMD3100, a selective antagonist of CXCR4, selected for the outgrowth of R5 virus after cultivation of mixtures of the laboratory-adapted R5 (BaL) and X4 (NL4-3) HIV strains in the presence of the compound. The addition of AMD3100 to peripheral blood mononuclear cells infected with X4 or R5X4 clinical HIV isolates displaying the syncytium-inducing phenotype resulted in a complete suppression of X4 variants and a concomitant genotypic change in the V2 and V3 loops of the envelope gp120 glycoprotein. The recovered viruses corresponded genotypically and phenotypically to R5 variants in that they could no longer use CXCR4 as coreceptor or induce syncytium formation in MT-2 cells. Furthermore, the phenotype and genotype of a cloned R5 HIV-1 virus converted to those of the R5X4 virus after prolonged culture in lymphoid cells. However, these changes did not occur when the infected cells were cultured in the presence of AMD3100, despite low levels of virus replication. Our findings indicate that selective blockade of the CXCR4 receptor prevents the switch from the less pathogenic R5 HIV to the more pathogenic X4 HIV strains, a process that heralds the onset of AIDS. In this article, we show that it could be possible to redirect the evolution of HIV so as to impede the emergence of X4 strains or to change the phenotype of already-existing X4 isolates to R5.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10364306      PMCID: PMC112615          DOI: 10.1128/JVI.73.7.5577-5585.1999

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry?

Authors:  Y J Zhang; J P Moore
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

2.  A new classification for HIV-1.

Authors:  E A Berger; R W Doms; E M Fenyö; B T Korber; D R Littman; J P Moore; Q J Sattentau; H Schuitemaker; J Sodroski; R A Weiss
Journal:  Nature       Date:  1998-01-15       Impact factor: 49.962

3.  Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4.

Authors:  A Peled; I Petit; O Kollet; M Magid; T Ponomaryov; T Byk; A Nagler; H Ben-Hur; A Many; L Shultz; O Lider; R Alon; D Zipori; T Lapidot
Journal:  Science       Date:  1999-02-05       Impact factor: 47.728

4.  Evidence for the HIV-1 phenotype switch as a causal factor in acquired immunodeficiency.

Authors:  S Glushakova; J C Grivel; W Fitzgerald; A Sylwester; J Zimmerberg; L B Margolis
Journal:  Nat Med       Date:  1998-03       Impact factor: 53.440

5.  Emergence of syncytium-inducing human immunodeficiency virus type 1 variants coincides with a transient increase in viral RNA level and is an independent predictor for progression to AIDS.

Authors:  I Spijkerman; F de Wolf; M Langendam; H Schuitemaker; R Coutinho
Journal:  J Infect Dis       Date:  1998-08       Impact factor: 5.226

6.  Apoptosis of CD8+ T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4.

Authors:  G Herbein; U Mahlknecht; F Batliwalla; P Gregersen; T Pappas; J Butler; W A O'Brien; E Verdin
Journal:  Nature       Date:  1998-09-10       Impact factor: 49.962

7.  Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1 disease progression.

Authors:  L Xiao; D L Rudolph; S M Owen; T J Spira; R B Lal
Journal:  AIDS       Date:  1998-09-10       Impact factor: 4.177

8.  CCR5- and CXCR4-utilizing strains of human immunodeficiency virus type 1 exhibit differential tropism and pathogenesis in vivo.

Authors:  R D Berkowitz; S Alexander; C Bare; V Linquist-Stepps; M Bogan; M E Moreno; L Gibson; E D Wieder; J Kosek; C A Stoddart; J M McCune
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

9.  The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract.

Authors:  K Tachibana; S Hirota; H Iizasa; H Yoshida; K Kawabata; Y Kataoka; Y Kitamura; K Matsushima; N Yoshida; S Nishikawa; T Kishimoto; T Nagasawa
Journal:  Nature       Date:  1998-06-11       Impact factor: 49.962

10.  Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development.

Authors:  Y R Zou; A H Kottmann; M Kuroda; I Taniuchi; D R Littman
Journal:  Nature       Date:  1998-06-11       Impact factor: 49.962

View more
  24 in total

1.  Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching.

Authors:  Cristina Pastore; Alejandra Ramos; Donald E Mosier
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

2.  ADS-J1 inhibits HIV-1 entry by interacting with gp120 and does not block fusion-active gp41 core formation.

Authors:  Emmanuel González-Ortega; Maria-Pau Mena; Marc Permanyer; Ester Ballana; Bonaventura Clotet; José A Esté
Journal:  Antimicrob Agents Chemother       Date:  2010-07-19       Impact factor: 5.191

3.  Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion.

Authors:  P Steinberger; J Andris-Widhopf; B Bühler; B E Torbett; C F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

4.  Viral entry through CXCR4 is a pathogenic factor and therapeutic target in human immunodeficiency virus type 1 disease.

Authors:  B Schramm; M L Penn; R F Speck; S Y Chan; E De Clercq; D Schols; R I Connor; M A Goldsmith
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

5.  Evolution of CXCR4-using human immunodeficiency virus type 1 SF162 is associated with two unique envelope mutations.

Authors:  Yana Kiselyeva; Rebecca Nedellec; Alejandra Ramos; Cristina Pastore; Leonid B Margolis; Donald E Mosier
Journal:  J Virol       Date:  2007-01-03       Impact factor: 5.103

6.  Inhibition of coreceptor-independent cell-to-cell human immunodeficiency virus type 1 transmission by a CD4-immunoglobulin G2 fusion protein.

Authors:  Berta Bosch; Julià Blanco; Eduardo Pauls; Imma Clotet-Codina; Mercedes Armand-Ugón; Boyan Grigorov; Delphine Muriaux; Bonaventura Clotet; Jean-Luc Darlix; José A Esté
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

7.  Evidence for common structural determinants of human immunodeficiency virus type 1 coreceptor activity provided through functional analysis of CCR5/CXCR4 chimeric coreceptors.

Authors:  S Pontow; L Ratner
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

8.  Tat-induced FOXO3a is a key mediator of apoptosis in HIV-1-infected human CD4+ T lymphocytes.

Authors:  Alicja Dabrowska; Nayoung Kim; Anna Aldovini
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

9.  Role of the human immunodeficiency virus type 1 envelope gene in viral fitness.

Authors:  Hector R Rangel; Jan Weber; Bikram Chakraborty; Arantxa Gutierrez; Michael L Marotta; Muneer Mirza; Patti Kiser; Miguel A Martinez; Jose A Este; Miguel E Quiñones-Mateu
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

10.  The entry of entry inhibitors: a fusion of science and medicine.

Authors:  John P Moore; Robert W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.